Notice of Results

RNS Number : 9191D
Oxford Biomedica PLC
03 April 2014







Oxford BioMedica: Notice of Preliminary Results

Results date: 10 April 2014



Oxford, UK - 03 April 2014: Oxford BioMedica plc (LSE: OXB), the leading gene-based biopharmaceutical company, will be announcing its preliminary results for the twelve months ended 31 December 2013 on Thursday, 10th April 2014.


An analyst briefing will be held at 09:30am GMT on Thursday, 10th April 2014 at the offices of Consilium Strategic Communications, 41 Lothbury, London, EC2R 7HG. The briefing will be hosted by John Dawson, Chief Executive Officer of Oxford BioMedica and Tim Watts, Chief Financial Officer.







For further information, please contact:



Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer


Tel: +44 (0)1865 783 000


Media Enquiries:

Mary-Jane Elliott/Emma Thompson/Matthew Neal

Consilium Strategic Communications



Tel: +44 (0)20 3709 5700


Note to editors


About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Oxford BioMedica has a broad range of partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at and



This information is provided by RNS
The company news service from the London Stock Exchange